Plot No. DG-12/1
Action Area 1D, Premises No. 02-0327
New Town, Rajarhat Kolkata 700 156
Phone: 91 33 66059750
Email: investors@surakshanet.com
Website: https://www.surakshanet.com/
Last updated on 03-Dec-2024 18:54:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 3837867 | 6667332 | 1.74 |
| HNIs | 2878400 | 4045218 | 1.41 |
| HNIs 10+ | 1918934 | 2929950 | 1.53 |
| HNIs 2+ | 959466 | 1115268 | 1.16 |
| Retail | 6716266 | 6352730 | 0.95 |
| Total | 13432533 | 17065280 | 1.27 |
Application-Wise Breakup (Approx. no. of Apps) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 4031 | 856 | 0.21 |
| HNIs (2-10L) | 2016 | 2115 | 1.05 |
| Retail | 197537 | 146281 | 0.74 |
| Total Applications: 149252 | |||
| © IPO Premium | |||
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIBs | 169.25 | 294.03 | 1.74 |
| FIIs | - | 29.66 | - |
| DIIs | - | 36 | - |
| Mutual funds | - | 222.3 | - |
| Others | - | 6.07 | - |
| HNIs | 126.94 | 178.39 | 1.41 |
| HNIs 10+ | 84.62 | 129.21 | 1.53 |
| HNIs 2+ | 42.31 | 49.18 | 1.16 |
| Retail | 296.19 | 280.16 | 0.95 |
| Total | 592.37 | 752.58 | 1.27 |
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹1 | @8% ₹1 | @9% ₹1 | @10% ₹1 | @11% ₹2 | @12% ₹2 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 34 | 14994 | 197537 |
| sHNI | 14 | 476 | 209916 | 2016 |
| bHNI | 67 | 2278 | 1004598 | 4031 |
Suraksha Clinic and Diagnostic IPO Details
| Issue Size | 19,189,330 shares (aggregating up to ₹[846.25] Cr) |
| Offer for Sale | 19,189,330 shares of ₹2 (aggregating up to ₹[846.25] Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 52,080,758 |
Suraksha Clinic and Diagnostic IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Net Offer |
Key Performance Indicator
| KPI | Jun-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 4.33% | 14.09% | 4.32% |
| ROCE | 6.32% | 21.46% | 9.05% |
| RONW | 4.33% | 14.09% | 4.32% |
| D/E | 0.16 | 0.2 | 0.27 |
| EPS (basic) | 1.49 | 4.43 | 1.22 |
| P/E Pre IPO | 99.31 |
Company Financials
Financial Information (Restated Consolidated)
(Amount in ₹ Crore)
Suraksha Diagnostic Limited's revenue increased by 14.75% and profit after tax (PAT) rose by 281.32% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period | Jun 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Assets | 314.20 | 300.21 | 281.20 | 275.96 |
| Revenue | 61.85 | 222.26 | 193.69 | 225.77 |
| Profit | 7.67 | 23.13 | 6.07 | 20.82 |
| Net Worth | 187.05 | 179.41 | 155.93 | 145.84 |
| Reserves | 176.80 | 170.88 | 147.40 | 137.31 |
| Borrowing | 7.57 | 8.64 | 14.01 | 19.03 |
About Company
Incorporated on March 15, 2005, Suraksha Diagnostic Limited is a technology-driven diagnostic chain offering integrated pathology, radiology, and medical consultancy services. The company provides a comprehensive portfolio of over 2,300 tests across various specialties, supported by a robust network comprising a central reference laboratory, 8 satellite laboratories, and 194 customer contact points, including 48 diagnostic centers and 146 sample collection centers. Additionally, 43 diagnostic centers house 120 polyclinics, staffed by over 750 doctors, offering both online and offline consultation services under one roof. Leveraging advanced technology systems such as Laboratory Information Management System (LIMS), Radiology Information System (RIS), Picture Archive Communication System (PACS), and Enterprise Resource Planning (ERP), the company enhances operational efficiency and reduces turnaround times. Suraksha Diagnostic also offers vaccination services and customized testing packages for early disease detection and prediction, utilizing digital pathology and AI-driven blood tests. All radiology reports are digitally processed, enabling seamless case reporting across centers.
Strength
Strong Market Position: A leading diagnostics chain in eastern and northeastern India, poised to capitalize on growth opportunities in the fragmented market.
Comprehensive Offerings: Integrated pathology, radiology, and medical consultancy services under one roof, supported by a wide network of diagnostic and sample collection centers.
Weakness
Geographic Concentration: Dependency on West Bengal for 95.48% of revenue exposes the company to regional risks that could adversely impact operations and financial performance.
Promoter Group Issues: Past suspension of securities of certain Promoter Group members raises concerns about reputation and potential challenges in raising future capital.
Intense Competition: Operating in a highly competitive diagnostics industry with a modest market share (1.15–1.30% in East India) could limit growth and profitability.